Literature DB >> 20118409

Role of the gap junction in ischemic preconditioning in the heart.

Tetsuji Miura1, Takayuki Miki, Toshiyuki Yano.   

Abstract

The gap junction plays roles not only in electrical coupling of cardiomyocytes but also in intercellular transport of biologically active substances. Furthermore, the gap junction participates in decision making on cell survival versus cell death in various types of cells, and a part of reperfusion injury in the heart has been indicated to be gap junction mediated. The contribution of gap junction communication (GJC) and/or mitochondrial "hemichannels" to protective signaling during the trigger phase of ischemic preconditioning (IPC) is suggested by observations that IPC failed to protect the heart when GJC was blocked during IPC. Although ischemia suppresses both electrical and chemical GJC, chemical GJC persists for a considerable time after electrical GJC is lost. IPC facilitates the ischemia-induced suppression of chemical GJC, whereas IPC delays the reduction of electrical GJC after ischemia. The inhibition of GJC during sustained ischemia and reperfusion by GJC blockers mimics the effect of IPC on myocardial necrosis. IPC induces distinct effects on the interaction of connexin-43 with protein kinases, and the phosphorylation of connexin-43 at Ser368 by PKCepsilon is a primary mechanism of inhibition of chemical GJC by IPC. Several lines of evidence support the notion that the modulation of GJC is a part of the mechanism of IPC-induced protection against myocardial necrosis and arrhythmias, though what percentage of IPC protection is attributable to the inhibition of GJC during ischemia-reperfusion still remains unclear.

Entities:  

Mesh:

Year:  2010        PMID: 20118409     DOI: 10.1152/ajpheart.00879.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  22 in total

Review 1.  Gap junctions.

Authors:  Morten Schak Nielsen; Lene Nygaard Axelsen; Paul L Sorgen; Vandana Verma; Mario Delmar; Niels-Henrik Holstein-Rathlou
Journal:  Compr Physiol       Date:  2012-07       Impact factor: 9.090

Review 2.  Connexins in the Heart: Regulation, Function and Involvement in Cardiac Disease.

Authors:  Antonio Rodríguez-Sinovas; Jose Antonio Sánchez; Laura Valls-Lacalle; Marta Consegal; Ignacio Ferreira-González
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 3.  Ischemic Conditioning and Atrial Fibrillation: Hope for a NewTherapy?

Authors:  Heiko Schmitt; Bruce T Liang; Christopher Pickett
Journal:  J Atr Fibrillation       Date:  2013-04-06

Review 4.  Pharmacological modulation of connexin-formed channels in cardiac pathophysiology.

Authors:  Elke De Vuyst; Kerstin Boengler; Gudrun Antoons; Karin R Sipido; Rainer Schulz; Luc Leybaert
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 5.  Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection.

Authors:  Rainer Schulz; Philipp Maximilian Görge; Anikó Görbe; Péter Ferdinandy; Paul D Lampe; Luc Leybaert
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

Review 6.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

7.  Glycogen synthase kinase 3β transfers cytoprotective signaling through connexin 43 onto mitochondrial ATP-sensitive K+ channels.

Authors:  Dennis Rottlaender; Kerstin Boengler; Martin Wolny; Astrid Schwaiger; Lukas J Motloch; Michel Ovize; Rainer Schulz; Gerd Heusch; Uta C Hoppe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-11       Impact factor: 11.205

8.  Inhibition of connexin 26 by the AMP-activated protein kinase.

Authors:  Ioana Alesutan; Mentor Sopjani; Carlos Munoz; Scott Fraser; Bruce E Kemp; Michael Föller; Florian Lang
Journal:  J Membr Biol       Date:  2011-03-12       Impact factor: 1.843

9.  Gap junctions and blood-tissue barriers.

Authors:  Michelle W M Li; Dolores D Mruk; C Yan Cheng
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

10.  Dual Effects of Bilirubin on the Proliferation of Rat Renal NRK52E Cells and ITS Association with Gap Junctions.

Authors:  Yanling Wang; Qiongfang Zhu; Chenfang Luo; Ailan Zhang; Ziqing Hei; Guangjie Su; Zhengyuan Xia; Michael G Irwin
Journal:  Dose Response       Date:  2012-07-30       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.